BeiGene
China's largest global biotech company focused on innovative oncology medicines
Company Overview
BeiGene is a global biotechnology company headquartered in China that is focused on developing innovative and affordable medicines for cancer patients worldwide. The company's BTK inhibitor Brukinsa has become one of the best-selling cancer drugs globally, and BeiGene has built a commercial presence in over 40 countries. BeiGene represents China's most successful biotech globalization story.
この企業が重要な理由
BeiGene has shattered the perception that Chinese biotech companies cannot compete globally, with Brukinsa becoming a blockbuster drug in the US and European markets.
主要注力分野
同業他社
シグナル活動
Signal Timeline
14 件BeiGene Announces Fourth Quarter and Full Year 2025 Financial Results
BeiGene announced its financial results for the fourth quarter and full year of 2025. The company highlighted key achievements and financial performance, providing insights into its operational progress and strategic advancements in the oncology sector. This report offers stakeholders a comprehensive overview of BeiGene's financial health and its ongoing commitment to developing innovative cancer treatments.
BeiGene Announces Q4 and Full Year 2025 Financial Results
BeiGene released its financial results for the fourth quarter and full year ended December 31, 2025. The report details the company's financial performance, including revenue, expenses, and profitability. This announcement is crucial for investors and stakeholders to assess BeiGene's financial health and strategic progress. The results provide insights into the company's operational efficiency and growth trajectory.
BeOne Medicines Announces Q4 and FY2025 Financial Results
BeOne Medicines reported its fourth quarter and full year 2025 financial results, highlighting the global success of its product BRUKINSA and its leadership in foundational oncology. The company's performance underscores its strategic growth and market penetration in key therapeutic areas.
BeiGene's PD-1 Inhibitor Tislelizumab Approved in Japan, Challenging Global Pharma Giants
BeiGene's anti-PD-1 antibody tislelizumab has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of non-small cell lung cancer. This marks a significant milestone as a Chinese-developed immunotherapy gains approval in one of the world's most stringent regulatory markets, directly competing with Merck's Keytruda and Bristol-Myers Squibb's Opdivo.
BeOne Medicines to Announce Q4 and Full Year 2025 Financial Results
BeOne Medicines announced that it will release its fourth quarter and full year 2025 financial results on February 26, 2026. The company will also host a conference call to discuss the results. This announcement provides investors with advance notice of the upcoming earnings report and an opportunity to engage with management.
BeiGene's Sonrotoclax Receives First-in-World Approval in R/R MCL
BeiGene announced that its novel BCL2 inhibitor, sonrotoclax, has received its first-in-world approval for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL). This regulatory milestone signifies a significant advancement in the treatment landscape for patients with this aggressive form of non-Hodgkin lymphoma, offering a new therapeutic option.
BeiGene's Novel BCL2 Inhibitor Sonrotoclax Receives First-in-World Approval
BeiGene's novel BCL2 inhibitor, Sonrotoclax, has received its first-in-world approval for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL). This regulatory milestone signifies a significant advancement in B-cell malignancy treatment, offering a new therapeutic option for patients with limited alternatives. The approval is based on robust clinical trial data demonstrating efficacy and safety.
Sonrotoclax Receives First-in-World Approval for R/R MCL and R/R CLL/SLL
BeOne Medicines' novel BCL2 inhibitor, Sonrotoclax, has achieved first-in-world approval for the treatment of relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) and R/R Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). This regulatory milestone marks a significant advancement in B-cell malignancy treatment.
この企業の新しいシグナルが公開されたら通知を受け取る。